Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Common Equity (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Common Equity for 16 consecutive years, with -$14.3 million as the latest value for Q4 2025.

  • For Q4 2025, Common Equity fell 162.66% year-over-year to -$14.3 million; the TTM value through Dec 2025 reached -$14.3 million, down 162.66%, while the annual FY2025 figure was -$14.3 million, 162.66% down from the prior year.
  • Common Equity hit -$14.3 million in Q4 2025 for Sangamo Therapeutics, down from $6.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $469.4 million in Q1 2021 and bottomed at -$14.3 million in Q4 2025.
  • Average Common Equity over 5 years is $194.9 million, with a median of $184.3 million recorded in 2023.
  • Year-over-year, Common Equity grew 19.02% in 2021 and then plummeted 162.66% in 2025.
  • Sangamo Therapeutics' Common Equity stood at $375.3 million in 2021, then dropped by 21.42% to $295.0 million in 2022, then tumbled by 71.9% to $82.9 million in 2023, then plummeted by 72.53% to $22.8 million in 2024, then tumbled by 162.66% to -$14.3 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$14.3 million, $6.2 million, and $19.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.